相似文献
1
From functions to mechanisms of the prototypic complement C5 antibody BB5.1.
Immunology. 2020 Oct;161(2):81-82. doi: 10.1111/imm.13261.
2
Characterizing the original anti-C5 function-blocking antibody, BB5.1, for species specificity, mode of action and interactions with C5.
Immunology. 2020 Oct;161(2):103-113. doi: 10.1111/imm.13228. Epub 2020 Jul 13.
3
Eculizumab-C5 complexes express a C5a neoepitope in vivo: Consequences for interpretation of patient complement analyses.
Mol Immunol. 2017 Sep;89:111-114. doi: 10.1016/j.molimm.2017.05.021. Epub 2017 Jun 10.
4
Current and future pharmacologic complement inhibitors.
Hematol Oncol Clin North Am. 2015 Jun;29(3):561-82. doi: 10.1016/j.hoc.2015.01.009. Epub 2015 Apr 4.
5
[C5: eculizumab].
Brain Nerve. 2014 Oct;66(10):1191-9. doi: 10.11477/mf.1416200008.
6
Structural Basis for Eculizumab-Mediated Inhibition of the Complement Terminal Pathway.
J Immunol. 2016 Jul 1;197(1):337-44. doi: 10.4049/jimmunol.1600280. Epub 2016 May 18.
7
Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn.
Immunobiology. 2015 Apr;220(4):452-9. doi: 10.1016/j.imbio.2014.11.003. Epub 2014 Nov 13.
8
Improving renal outcomes in chronic anemia: learning from paroxysmal nocturnal hemoglobinuria.
Am J Hematol. 2010 Aug;85(8):551-2. doi: 10.1002/ajh.21800.
9
Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation.
Blood. 2017 Feb 23;129(8):970-980. doi: 10.1182/blood-2016-08-732800. Epub 2016 Dec 27.
10
[Eculizumab in paroxysmal nocturnal hemoglobinuria].
Med Sci (Paris). 2009 Dec;25(12):1126-9. doi: 10.1051/medsci/200925121126.
本文引用的文献
1
Characterizing the original anti-C5 function-blocking antibody, BB5.1, for species specificity, mode of action and interactions with C5.
Immunology. 2020 Oct;161(2):103-113. doi: 10.1111/imm.13228. Epub 2020 Jul 13.
2
Complement, infection, and autoimmunity.
Curr Opin Rheumatol. 2019 Sep;31(5):532-541. doi: 10.1097/BOR.0000000000000633.
3
Development and characterization of novel anti-C5 monoclonal antibodies capable of inhibiting complement in multiple species.
Immunology. 2019 Aug;157(4):283-295. doi: 10.1111/imm.13083. Epub 2019 Jun 17.
4
The essential role of complement in antibody-mediated resistance to Salmonella.
Immunology. 2019 Jan;156(1):69-73. doi: 10.1111/imm.13000. Epub 2018 Oct 10.
5
Characterizing a pH-switch anti-C5 antibody as a tool for human and mouse complement C5 purification and cross-species inhibition of classical and reactive lysis.
Immunology. 2018 Nov;155(3):396-403. doi: 10.1111/imm.12982. Epub 2018 Jul 30.
6
C5a induces caspase-dependent apoptosis in brain vascular endothelial cells in experimental lupus.
Immunology. 2016 Aug;148(4):407-19. doi: 10.1111/imm.12619. Epub 2016 Jul 11.
7
Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis.
Clin Exp Immunol. 2010 Mar;159(3):303-14. doi: 10.1111/j.1365-2249.2009.04070.x. Epub 2009 Dec 4.
8
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
Nat Biotechnol. 2007 Nov;25(11):1256-64. doi: 10.1038/nbt1344.
9
The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice.
Clin Exp Immunol. 2006 Nov;146(2):294-302. doi: 10.1111/j.1365-2249.2006.03205.x.
10
Generation of a monoclonal antibody to mouse C5 application in an ELISA assay for detection of anti-C5 antibodies.
Mol Cell Probes. 1987 Jun;1(2):141-9. doi: 10.1016/0890-8508(87)90022-3.
Zotero 插件